SMi Group announces the 9th Annual RNA Therapeutics Conference

SMi Group21 - 22 February 2018, London, UK.
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion. One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and evaluate with key industry leaders the lessons they’ve learnt whilst developing an RNA therapeutic.

Join RNA Therapeutics this February 2018, as SMi's RNA Therapeutics Conference brings together industry experts from leading RNA therapeutics companies to analyze and evaluate the latest advancements including SaRNA as a potential therapeutic for people with liver cancer, advances in targeted delivery of nucleotides beyond the liver and the latest developments in delivery systems, such as exosomes and nanocomplexes.

How Will You Benefit?

Network and learn from leading professionals such as:
  • Nagy Habib, Head of HPB Surgery, Imperial College London and Co-Founder, MiNA Therapeutics
  • Shalini Andersson, Senior Director Drug Metabolism & Pharmacokinetics, AstraZeneca R&D
  • Ekkehard Leberer, Senior Director, Sanofi
  • Jeffrey Ulmer, Head Preclinical R&D, GSK
  • James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals
  • Mariola Fotin-Mleczek, Chief Scientific Officer, CureVac
  • Bob D. Brown, Chief Scientific Officer and Senior Vice President, Research, Dicerna Pharmaceuticals
  • Oliver Rausch, VP Research & Development, Storm Therapeutics
  • Kirsty Wydenbach, Senior Medical Assessor, Deputy Unit Manager, Clinical Trials Unit, MHRA

Some Featured Highlights will include:

  • Hear from MiNA Therapeutics about their new pre-clinical data supporting the on-target mechanism of action of their pioneering new drug candidate MTL-CEBPA
  • Learn how CureVac's sophisticated technologies and approaches have helped overcome limitations such as the instability of single-stranded RNA
  • Discover STORM Therapeutics’ innovative approach: Harnessing the power of RNA epigenetics to develop first-inclass drugs in oncology
  • Expand your knowledge of patenting RNA Therapeutics, with James Ogle, a European and UK Chartered Patent Attorney with particular expertise in RNA and other nucleic acid based technologies
  • Examine the latest developments in delivery systems for RNA Therapeutics, including Exosomes, Nanocomplexes and Platform Delivery Approaches

Early-Bird Rates

Book by 30th November and save £200
Book by 15th December and save £100

For further information and to register, please visit:
http://www.therapeutics-rna.com/wpn

About SMi Group
The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Top 20 breaking World Pharma News of 2017

We are proud to announce the top 20 most popular breaking World Pharma News from 2017. Have a wonderful 2018 new(s) year filled with health, happiness, and spectacular su...

Roche and Ignyta reach definitive merger agreement

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta ...

Antidepressant may help combat the course of multi…

The antidepressant clomipramine may also alleviate symptoms of multiple sclerosis (MS), specifically in its progressive form, i.e. when it occurs without relapses or remi...

Novartis advances head-to-head superiority trials …

Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondyl...

Distinct human mutations can alter the effect of m…

Every person has a unique DNA sequence in their genome. Now researchers from the University of Copenhagen and the MRC Laboratory of Molecular Biology in Cambridge have tr...

FDA updates the label of Tasigna to reflect that c…

The U.S. Food and Drug Administration today updated the product label for the cancer drug Tasigna (nilotonib) to include information for providers about how to discontinu...

Zika remains a research and public health challeng…

Since 2016, when Zika was declared by the World Health Organization as a public health emergency of international concern, the virus has become established in more than 8...

FDA approves novel gene therapy to treat patients …

The U.S. Food and Drug Administration today approved Luxturna (voretigene neparvovec-rzyl), a new gene therapy, to treat children and adult patients with an inherited for...

Diabetes drug 'significantly reverses memory loss…

A drug developed for diabetes could be used to treat Alzheimer's after scientists found it "significantly reversed memory loss" in mice through a triple method of action...

Try exercise to improve memory, thinking

For patients with mild cognitive impairment, don't be surprised if your health care provider prescribes exercise rather than medication. A new guideline for medical pract...

Arthritis drug could help treat advanced skin canc…

Treatment for the most deadly form of skin cancer could be more effective if combined with a well-known drug for rheumatoid arthritis, new research has shown. The study, ...

Novartis Kisqali® received FDA Breakthrough Therap…

Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pr...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]